PMS63 - COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1777
https://www.valueinhealthjournal.com/article/S1098-3015(18)35079-4/fulltext
Title :
PMS63 - COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35079-4&doi=10.1016/j.jval.2018.09.1777
First page :
Section Title :
Open access? :
No
Section Order :
1142